Chemotherapy News and Research

Latest Chemotherapy News and Research

Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy

Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.

22 Sep 2009

Barbershop singing helps cancer-survivor

For Marguerite Paustenbach, her secret weapon in the fight against breast cancer turned out to be her strong faith and love for barbershop singing. Paustenbach is a member of Village Vocal Chords, a Chicago-based barbershop singing group that’s part of Harmony, Inc., an all women’s barbershop singing organization currently celebrating its 50th anniversary.

22 Sep 2009

Tregs to set the pace of recovery after serious lung injury

After more than 50 experiments in mice, medical scientists at Johns Hopkins have mapped out the basic steps taken by a particular set of white blood cells in setting the pace of recovery after serious lung injury.

22 Sep 2009

Investigative drug hampers the survival of non-Hodgkin lymphoma cells

An investigative drug deprived non-Hodgkin lymphoma cells of their ability to survive too long and multiply too fast, according to an early study published recently in the journal Experimental Hematology.

22 Sep 2009

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

Data published today in The Lancet showed a survival benefit in nonsquamous patients with advanced non-small cell lung cancer (NSCLC) who received maintenance therapy with ALIMTA(R) (pemetrexed for injection) plus best supportive care as compared to placebo plus best supportive care.

21 Sep 2009

Nasdaq Stock Market issues noncompliance letter to A.P. Pharma

A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that, on September 15, 2009, the Company received a letter from The Nasdaq Stock Market (Nasdaq) indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, A.P. Pharma was not in compliance with Marketplace Rule 5450(a)(1).

21 Sep 2009

MedWaves reports on its ongoing studies using the AveCure microwave coagulation-ablation system

MedWaves, Inc. announces ongoing investigational studies to determine the effectiveness of its microwave ablation system for treating soft tissue lesions, such as tumors, in liver and lung. The studies using MedWaves' AveCure(TM) microwave coagulation-ablation system, which includes a generator and probe/antenna (FDA 510(k) cleared and CE Mark certified), are showing promising results.

19 Sep 2009

FDA continues review of BSD Medical's HDE for the BSD-2000 Hyperthermia System

BSD Medical Corporation (NASDAQ: BSDM) (www.bsdmedical.com) reported today that the U.S. Food and Drug Administration (FDA) continues its review of the Company's Humanitarian Device Exemption (HDE) marketing submission for the Company’s BSD-2000 Hyperthermia System.

19 Sep 2009

EPO and growth factor therapy safe for anemic MDS patients

Myelodysplastic syndromes (MDS), a group of blood disorders that can lead to acute myeloid leukemia (AML) in some patients, often cause severe anemia (when the body lacks a sufficient number of functional red blood cells).

18 Sep 2009

Research to identify breast cancer disparities

In an effort to continue to deliver on its vision of a world without breast cancer, Susan G. Komen for the Cure,((R) )San Diego conducted an in-depth, county-wide research and community needs assessment to identify disparities in breast cancer across populations.

18 Sep 2009

Researchers study the role of stem cells in development of liver cancer

Penn State College of Medicine researchers, in collaboration with colleagues at the University of Southern California, have taken an important step in understanding the role of stem cells in development of liver cancer.

18 Sep 2009

Notice of Allowance issued by PTO for OSI's EGFR drug

OSI Pharmaceuticals, Inc. announced today that the U.S. Patent & Trademark Office has issued a “Notice of Allowance” in OSI’s reissue application for U.S. Patent No.5,747,498 (the ‘498) composition of matter patent for Tarceva® (erlotinib). The reissued patent will replace the original ‘498 patent and have the same November 2018 expiration date.

18 Sep 2009

Drug carrier that cuts off blood supply to tumors

To that end, Dr. Ronit Satchi-Fainaro of Tel Aviv University's Department of Physiology and Pharmacology, Sackler School of Medicine, and her team of researchers have developed a new drug carrier to deliver compounds straight to the tumor.

18 Sep 2009

Deterioration in brain function following breast cancer therapy has negative effects on quality of life

One of the most problematic side effects of cancer treatment, chemobrain - a range of symptoms including memory loss, inability to concentrate, difficulty thinking and other subtle cognitive changes following chemotherapy - seriously diminishes women's quality of life and daily functioning.

18 Sep 2009

Quebec research on contagious period of H1N1 patients to be presented

Members of a group of Quebec researchers will be presenting the preliminary results of their work on Influenza A (H1N1) tomorrow at the Interscience Conference on Antimicrobial Agents and Chemotherapy, a prestigious international conference that the American Microbiology Association is currently presenting in San Francisco.

18 Sep 2009

Second-quarter fiscal 2009 results announced by Gentium

Gentium S.p.A. (NASDAQ: GENT) today reported financial results for the second quarter ended June 30, 2009.

17 Sep 2009

Cancer patients struggles with huge drug costs

Canada's patchwork system of drug coverage is leading to financial hardship for many cancer patients, says a Canadian Cancer Society report released today.

17 Sep 2009

Deterioration in brain function following breast cancer therapy affects quality of life: Study

17 Sep 2009

CI Index of ten leading cancer immunotherapy stocks increase by 58% in two months

The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks has increased 58% in its first two months of reporting. CI Index gain was paced by the 233% share price improvement of ImmunoCellular Theraputics, Inc. (IMUC.OB) under the leadership of CEO Manish Singh, Ph. D.

17 Sep 2009

Mayo Clinic Women's HealthSource discusses myths and facts about ovarian cancer

But not all the news about ovarian cancer is grim. Incidence is declining. Doctors are learning more about early symptoms and more effective treatments. The September issue of Mayo Clinic Women's HealthSource looks at myths and facts about ovarian cancer.

17 Sep 2009